Pseudouridimycine: New natural antibiotic capable of destroying resistant bacteria

Antibiotic-resistant bacteria, popularly known as ‘superbugs’, are one of the major threats to global public health. These microorganisms have once evolved to counteract the efficacy of antibiotics – usually by abusive or improper use of these drugs, in the case of their use in the treatment of diseases, such as influenza, caused by Virus and not a bacterium – little more can be done than committing to the patient’s immune system’s ability to fight infection.

In addition, the number of ongoing studies to develop new antibiotics is negligible, so the future does not seem to be too hopeful.

So what can you do? For example, look at Nature to see if, as happened in the discovery – accidental – of penicillin, there is a new compound capable of dealing with these resistant bacteria. One possibility that, as a study led by researchers at Rutgers University in New Brunswick, USA, can show some remarkable results.>

Specifically, the study, published in the journal “Cell”, describes an antibiotic that is naturally produced by a bacterium and dubbed “pseudouridimycina”, has a novel mechanism of action capable of destroying a broad spectrum of both sensitive and resistant bacteria. The antibiotics available and to cure bacterial infections in animal models – mice.

As explained by Stefano Donadio, co-director of the research, “among other results, our work highlights the importance of natural products to provide new antibiotics. And it’s that microbes have been billions of years developing ‘chemical weapons’ to kill other microbes.”

The antibiotic pseudouridimycine acts by inhibiting bacterial RNA polymerase, that is, the enzyme responsible for synthesizing the RNA of the bacteria. However, to date there is another available antibiotic which, called ‘rifampicin’, also acts by inhibiting this bacterial enzyme.

So, should bacteria resistant to rifampicin be expected to be resistant to pseudouridimycine? Well, no, since both its mechanisms and enzyme binding sites are different. This is so when they are administered in combination they add their antibiotic effects.

It’s more, the rate of spontaneous resistance of pseudouridimycine is only one tenth of that of rifampicin; in other words, the probability that a bacterium develops resistance to pseudouridimycine as a result of a spontaneous mutation is 10 times lower than that observed with rifampicin.

Specifically, pseudouridimycine acts as an analogous nucleoside inhibitor in bacterial RNA polymerase. That is, it mimics chemical compounds which, like building blocks, are used by the enzyme to synthesize bacterial RNA. Thus, what the antibiotic does is bind to RNA polymerase in the place where the building blocks – a molecule called ‘nucleoside triphosphate’ (NTP) – would do. And since the NTP can no longer be bound, the enzyme does not have the raw material to construct the RNA.

And does not this new antibiotic, as it does with the bacterial enzyme, also inhibit human RNA polymerase? Well, no. Pseudouridimycine is the first nucleoside analogue to selectively inhibit bacterial RNA polymerase but not human RNA polymerases.

As Richard H. Ebright, co-director of research, indicates, “since the point of attachment of NTP to bacterial RNA polymerase has exactly the same structure and sequence as the point of attachment of NTP to human RNA polymerase, most of the researchers believed it impossible that an analogous nucleoside inhibitor could inhibit bacterial RNA polymerase without doing the same with human. However, the pseudouridimycine contains a side chain that remains outside the point of attachment of the NTP and touches an adjacent point present in bacterial but not human RNA polymerase. The result is that the antibiotic binds much more strongly to the bacterial enzyme than to the human enzyme.

It’s more; as the authors point out, the fact that pseudouridimycine acts as an analogous nucleoside inhibitor explains the low rate of spontaneous antibiotic resistance.

As Richard H. Ebright reports, “the new antibiotic interacts with essential residues at the point of attachment of NTP that can not be altered without losing the activity of RNA polymerase and thus the viability of the bacterium. The alterations at the point of attachment of the NTP that prevent the new antibiotic from joining also make bacterial activity impossible, so that the bacterium eventually dies before it develops resistance.

In definitive, pseudouridimycine appears as a very promising drug to combat the increasingly pressing problem of bacterial resistance.

Share with

Back to Blog

OCC’s epidemiologist is closely monitoring the COVID-19 status and is actively issuing updates as they are available. The Centers for Disease Control and the World Health Organization are the most trusted sources online.  While the CDC has announced new mask protocols for vaccinated individuals, there will be no changes for our office protocols for patients, guests, and staff members as the announcement does not apply to hospitals or medical facilities. Masks are still a requirement for all patients, guests and staff at our facility.

As we reinitiate weight loss surgery, we are constantly adapting and installing new and updated safety measures.

Weight loss surgery is medically necessary.

Bariatric Surgery and the clash of two pandemics.   

Major metabolic and bariatric surgery Societies and colleges globally are now calling for the safe resumption of bariatric and metabolic surgery before the COVID-19 pandemic is declared over. 

The sooner bariatric surgery can be safely performed, the quicker obesity, type 2 diabetes, and other diseases can be reduced or resolved as they are not only chronic they are also progressive.  Obesity is also linked to more than 40 diseases including type 2 diabetes, hypertension, heart disease, stroke, sleep apnea, osteoarthritis, and at least 13 different types of cancer.

A recent statement from the ASMBS says “Before COVID-19 began, it was clear that patients with obesity were ‘safer through surgery.’ In the era of COVID-19, ‘safer through surgery’ for patients with obesity may prove to be even more important than before.” Obesity and Metabolic syndrome have been identified as an independent risk factor for adverse outcomes including death among COVID-19 patients.

See here for full COVID-19 update. 

Contact us media
Contact Us
Accessibility: If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact our Accessibility Manager at 866-376-7849.
Contact Us